The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Emerging Agents for T790M-Mutant Patients With NSCLC

Howard L. (Jack) West, MD
Published Online: 2:52 AM, Tue June 7, 2016
Howard L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses emerging agents on the horizon for patients with T790M-mutant patients with non-small cell lung cancer (NSCLC).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.